David Levenson, MD
Endocrinology, Diabetes & Metabolism · Boca Raton, FLNPI 1194808063
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 183 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,002, 2.8 times the $364 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in FL, where the typical reported total is $3,445.
Across 183 payments — averaging $20.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$852
- Amgen$445
- Corcept Therapeutics$346
- Medicure Pharma Inc.$209
- Bayer$177
- Mannkind Corporation$175
- plus $2K from 30 others
Across 370 payments — averaging $543.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$201K
What the payments were for
- Speaking & faculty fees$140%
- Food & beverage$3,77399%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 44 | $852 |
| Amgen(2 entities) | 18 | $445 |
| Corcept Therapeutics | 21 | $346 |
| Medicure Pharma Inc. | 2 | $209 |
| Bayer | 8 | $177 |
| Mannkind Corporation | 10 | $175 |
| Dexcom, Inc. | 10 | $171 |
| Lilly USA, LLC | 10 | $167 |
| Edwards Lifesciences | 2 | $141 |
| Sanofi | 1 | $125 |
| Recordati_rare_diseases_inc. | 6 | $97 |
| Neurocrine Biosciences, Inc. | 4 | $88 |
| Xeris Pharmaceuticals, Inc. | 5 | $84 |
| Kyowa Kirin, Inc. | 3 | $58 |
| Novartis | 3 | $57 |
| Amneal Pharmaceuticals LLC | 4 | $56 |
| Merck | 3 | $50 |
| Abbott | 3 | $45 |
| Boehringer Ingelheim | 2 | $43 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Madrigal Pharmaceuticals | 2 | $39 |
| Novo Nordisk | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Senseonics, Incorporated | 2 | $33 |
| Sequel Med Tech, LLC | 1 | $30 |
| AbbVie(2 entities) | 2 | $29 |
| AstraZeneca | 2 | $28 |
| Viiv Healthcare Company | 1 | $23 |
| Insulet Corporation | 1 | $22 |
| Valeritas, Inc. | 1 | $19 |
| Alvogen Inc | 1 | $19 |
| Medtronic | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Roche Diabetes Care, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZYPITAMAG (pitavastatin)$195
- TEPEZZA$125
How this compares
$3,823 in reported general payments places this provider in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 352 | $495,761 |
| KorlymMifepristone | 13 | $370,304 |
| MounjaroTirzepatide | 268 | $366,454 |
| JardianceEmpagliflozin | 200 | $283,350 |
| TrulicityDulaglutide | 164 | $207,345 |
| JanuviaSitagliptin Phosphate | 136 | $147,897 |
| VascepaIcosapent Ethyl | 141 | $118,036 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 67 | $84,903 |
| Tresiba Flextouch U-100Insulin Degludec | 116 | $70,137 |
| FarxigaDapagliflozin Propanediol | 39 | $56,288 |
| RybelsusSemaglutide | 35 | $56,120 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 47 | $52,222 |
| TradjentaLinagliptin | 44 | $42,957 |
| SynthroidLevothyroxine Sodium | 563 | $41,821 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 110 | $32,655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $167 | $573,799432 claims |
| Novo NordiskOzempic, Rybelsus | $34 | $551,881387 claims |
| Corcept TherapeuticsKorlym | $346 | $370,30413 claims |
| Boehringer IngelheimJardiance, Tradjenta | $43 | $326,308244 claims |
| MerckJanuvia, Janumet Xr | $50 | $164,283151 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $852 | $84,90367 claims |
| AstraZenecaFarxiga | $28 | $56,28839 claims |
| AbbVieSynthroid | $29 | $41,821563 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $56 | $20,0801,627 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $34 | $10,53922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Boca Raton
- Irina RobinsonBoca Raton$65K
- Vineeth MohanBoca Raton$51K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.